• Galenea Corp., of Cambridge, Mass., and collaborator Kevin Spencer, of the VA Boston Healthcare System and Harvard Medical School, were awarded a five-year, $3 million grant from the National Institute of Mental Health to fund the development of new biomarkers based on brain wave oscillations in animal models of psychosis and in human schizophrenia patients.